Furthermore, the role of GLP-1 RAs in the treatment of nonalcoholic fatty liver disease (NAFLD) [23] and nonalcoholic steatohepatitis (NASH) [24], the aggressive form of NAFLD, has been the focus of medical research in recent years, as the high prevalence of NAFLD among people with T2D and obesity, and the pathophysiological links between these entities, raise the expectation that patients can derive common benefits from GLP-1 RA therapy [25]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.